All In Biotech

NDA 050777 · Leo Pharma As

Protopic

Tacrolimus · Topical

Last checked: Nov 20, 2026Latest source record: Feb 25, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Dec 8, 2000

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,405

234 Phase 3, 122 recruiting

FAERS reports

127,270

114,770 serious, 20,093 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 15, 2021.

INDICATIONS AND USAGE Tacrolimus Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus Ointment is not indicated for children younger than 2 years of age (see boxed WARNING , WARNINGS and PRECAUTIONS: Pediatric Use ).

Mechanism: Mechanism of Action The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This effect has been shown to prevent the dephosphorylation and translocation of nuclear factor of activated...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PROTOPIC · TACROLIMUS 0.1% · OINTMENT, TOPICAL · Prescription · TE AB
  • PROTOPIC · TACROLIMUS 0.03% · OINTMENT, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.

All 1,405 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use13,183
  • drug ineffective9,050
  • product use in unapproved indication6,162
  • drug interaction5,625
  • acute kidney injury5,528
  • diarrhoea4,584
  • transplant rejection4,146
  • cytomegalovirus infection4,080
  • pyrexia3,872
  • covid-193,755
  • toxicity to various agents3,717
  • pneumonia3,638

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005219
2006259
2007555
2008951
20091,053
20101,201
20112,205
20122,459
20131,608
20142,523
20153,006
20164,184
20176,098
20189,100
20199,393
202010,998
202110,770
202211,191
202312,612
202413,674
202513,561
20269,481

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,850 on PubMed

Sponsor: Leo Pharma As

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.